Medicines Co drug shows long-term cholesterol lowering in study

WASHINGTON (Reuters) - A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday.